Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available data.

Journal: Diabetologia
Published Date:

Abstract

The type 1 diabetes community is coalescing around the benefits and advantages of early screening for disease risk. To be accepted by healthcare providers, regulatory authorities and payers, screening programmes need to show that the testing variables allow accurate risk prediction and that individualised risk-informed monitoring plans are established, as well as operational feasibility, cost-effectiveness and acceptance at population level. Artificial intelligence (AI) has the potential to contribute to solving these issues, starting with the identification and stratification of at-risk individuals. ASSET (AI for Sustainable Prevention of Autoimmunity in the Society; www.asset.healthcare ) is a public/private consortium that was established to contribute to research around screening for type 1 diabetes and particularly to how AI can drive the implementation of a precision medicine approach to disease prevention. ASSET will additionally focus on issues pertaining to operational implementation of screening. The authors of this article, researchers and clinicians active in the field of type 1 diabetes, met in an open forum to independently debate key issues around screening for type 1 diabetes and to advise ASSET. The potential use of AI in the analysis of longitudinal data from observational cohort studies to inform the design of improved, more individualised screening programmes was also discussed. A key issue was whether AI would allow the research community and industry to capitalise on large publicly available data repositories to design screening programmes that allow the early detection of individuals at high risk and enable clinical evaluation of preventive therapies. Overall, AI has the potential to revolutionise type 1 diabetes screening, in particular to help identify individuals who are at increased risk of disease and aid in the design of appropriate follow-up plans. We hope that this initiative will stimulate further research on this very timely topic.

Authors

  • Pedro F Teixeira
    Diamyd Medical AB, Stockholm, Sweden.
  • Tadej Battelino
  • Anneli Carlsson
    Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden.
  • Soffia Gudbjörnsdottir
    Swedish National Diabetes Register, Centre of Registers, Gothenburg, Sweden.
  • Ulf Hannelius
    Diamyd Medical AB, Stockholm, Sweden.
  • Matthias von Herrath
    Global Chief Medical Office, Novo Nordisk, A/S, Søborg, Denmark.
  • Mikael Knip
    Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Olle Korsgren
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Helena Elding Larsson
    Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden.
  • Anton Lindqvist
    Diamyd Medical AB, Stockholm, Sweden.
  • Johnny Ludvigsson
    Crown Princess Victoria Children's Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
  • Markus Lundgren
    Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
  • Christoph Nowak
    Diamyd Medical AB, Stockholm, Sweden.
  • Paul Pettersson
    Division of Networked and Embedded Systems, Mälardalen University, Västerås, Sweden.
  • Flemming Pociot
    Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Frida Sundberg
    Department of Paediatrics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Karin Åkesson
    Department of Clinical and Experimental Medicine, Division of Pediatrics and Diabetes Research Center, Linköping University, Linköping, Sweden.
  • Åke Lernmark
    Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden. ake.lernmark@med.lu.se.
  • Gun Forsander
    Department of Paediatrics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. gun.forsander@pediat.gu.se.